Answers are grounded in this paper and cite their sources.
Importance Blood biomarkers that reflect neurofibrillary tau burden, a defining hallmark of Alzheimer disease (AD), remain limited. Endogenously cleaved microtubule-binding region tau 243 (eMTBR-tau243) has shown promise when measured by mass spectrometry; a scalable immunoassay could broaden research access and support clinical evaluation. Objective To determine whether plasma levels of eMTBR-tau measured by a novel immunoassay are associated with tau neurofibrillary tangle pathology defined by neuropathology and tau positron emission tomography (PET). Design, Setting, and Participants This cross-sectional study included brain donors with antemortem plasma from 2 US autopsy cohorts, and individuals with plasma samples and tau PET from 2 imaging cohorts in Canada and Sweden, with visits between 2002 and 2025 depending on the cohort. Exposures Plasma eMTBR-tau measured with an immunoassay and eMTBR-tau243 measured with mass spectrometry. Main Outcomes and Measures Plasma eMTBR-tau levels across neuropathologic Braak neurofibrillary tangle stages (I-VI, ranging from tangles confined to the entorhinal region to widespread neocortical tangles) and tau-PET Braak stages (0-VI), expressed as fold changes. Correlations with regional tau-PET standardized uptake value ratios (SUVRs; higher values indicating more tau tangles), discrimination of regional tau-PET positivity (area under the curve [AUC]), and correlation with mass spectrometry–based eMTBR-tau243. Results The study included 728 participants in 4 cohorts (median age by cohort, 71.0-83.5 years; 41.3%-56.6% female). In the 2 autopsy cohorts (n = 241 and n = 240), eMTBR-tau age- and sex-adjusted geometric means were 0.0021 pg/mL and 0.0040 pg/mL, respectively, at Braak stages I-II vs 0.107 pg/mL and 0.101 pg/mL at Braak stage VI (50.5-fold [95% CI, 26.3-97.0] and 25.2-fold [95% CI, 15.8-40.3] higher for stage VI vs stages I-II; P < .001 for both cohorts). In one imaging cohort (n = 99), compared with tau-PET Braak stage 0, eMTBR-tau levels were 11.0-fold (95% CI, 6.9-17.5) higher at stages III-IV and 59.9-fold (95% CI, 39.5-90.7) higher at stages V-VI. Among participants positive for amyloid-β (Aβ) in another imaging cohort (n = 50), the Spearman rank correlations for eMTBR-tau with tau-PET SUVRs were ρ = 0.52 (95% CI, 0.28-0.70) in Braak regions I-II, 0.76 (95% CI, 0.61-0.86) in regions III-IV, and 0.85 (95% CI, 0.75-0.91) in regions V-VI (all P < .001). Immunoassay and mass spectrometry measurements were strongly correlated (Spearman rank correlation, ρ = 0.93 in all participants [n = 108] and ρ = 0.96 in Aβ-positive participants [n = 54]) and discriminated tau-PET positivity similarly (n = 102; AUC range, 0.96-0.99 for the immunoassay and 0.97-0.99 for mass spectrometry). Conclusions and Relevance A plasma eMTBR-tau immunoassay identified neocortical tau pathology in autopsy and tau-PET cohorts and correlated strongly with mass spectrometry measurements, a proof of principle that eMTBR-tau can be measured by immunoassay as a marker of advanced neurofibrillary tangle pathology.
No takes yet. Share an insight, caveat, or question.
Brum et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: